The association between metabolic syndrome and hepatocellular carcinoma: Systemic review and meta-analysis

Journal of Clinical Gastroenterology

Volumn 48, Issue 2, 2014, Pages 172-177

  Jinjuvadia, Raxitkumar ^a   Patel, Suhag ^a   Liangpunsakul, Suthat ^b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatoma; liver cancer; metabolic abnormalities

Indexed keywords

CANCER RISK; COHORT ANALYSIS; DATA EXTRACTION; DISEASE ASSOCIATION; EUROPE; HUMAN; JAPAN; LIVER CELL CARCINOMA; MAGNITUDE ESTIMATION METHOD; MEDICAL LITERATURE; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; PUBLICATION QUALITY; PUBLISHING; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; METABOLIC SYNDROME X; PUBLICATION BIAS; RISK ASSESSMENT;

EID: 84892942788     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a030c4     Document Type: Review

References (33)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127
2. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link. Cancer. 2009;115:5651-5661
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421
4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-Aged men. JAMA. 2002;288:2709-2716
5. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169:1505-1522
6. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: The European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila). 2011;4:1873-1883
7. Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:1646-1650
8. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884-889
9. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: A meta-Analysis of cohort studies. Br J Cancer. 2007;97:1005-1008
10. Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: A systematic review and metaanalysis. Diabetes Metab Res Rev. 2012;28:109-122
11. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131:193-200
12. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database. Hepatology. 2011;54:463-471
13. Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553
16. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: A new worldwide definition. Lancet. 2005;366:1059-1062
17. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438
18. Hogue CJ, Gaylor DW, Schulz KF. Estimators of relative risk for case-control studies. Am J Epidemiol. 1983;118:396-407
19. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46
20. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses. 2011. Available at: Http://www.ohri.ca/programs/clinical-epidemiology/oxford-web. ppt
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-Analysis. Stat Med. 2002;21:1539-1558
22. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629-634
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101
24. Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: Results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18:240-247
25. Osaki Y, Taniguchi S, Tahara A, et al. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36:141-147
26. Cohen's kappa calculator. Available at: Http://www.vassar stats.net/kappa.html. Accessed 2012
27. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4: 369-380
28. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938-1946
29. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. Hepatology. 2009;49:851-859
30. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr. 2007;86:s836-s842
31. Leu CM, Wong FH, Chang C, et al. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-Activated protein kinase pathways. Oncogene. 2003;22:7809-7818
32. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124: 2766-2770
33. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12:13-21